Alan H. Bryce,MD

Alan H. Bryce, MD, joined City of Hope^® in November 2023 as the Chief Clinical Officer at City of Hope Cancer Center Phoenix and Professor of Molecular Medicine at the Translational Genomics Research Institute (TGen), also part of City of Hope. Dr. Bryce is the region’s senior clinical leader, guiding care across all City of Hope locations in the Phoenix area, including the cancer center in Goodyear and Outpatient Care Centers in Gilbert, North Phoenix and Scottsdale. He is a key partner in developing and implementing clinical research in the region and in ensuring compliance with clinical, research, academic, quality and safety goals, and standards.

Dr. Bryce is renowned for his longstanding commitment to patient-centered cancer care, with a focus on reducing health equity, enhancing patients’ access to top-quality care and protecting patients’ quality of life while continuing research with the goal of curing cancer. Board certified in internal medicine and medical oncology, he treats prostate cancer with a special emphasis on individualized medicine, while devoting his research to developing new therapies and cancer genetics approaches to prostate cancer.

“One of the encouraging aspects of modern cancer care as an academic oncologist is the fact that we have to reinvent ourselves every five years or so to help drive our rapid progress,” he says. “Oncology is a fast-changing field. What we do today is nothing like it was 10 years ago, which in turn was nothing like it was during my fellowship. That pace of change gives me hope that we will continue to find cures for cancer and reduce the suffering from this group of diseases.”

His appointment at TGen amplifies the opportunities for City of Hope’s clinical sites to advance scientific discoveries made at the research institute.

“My intent is to fully integrate all the expertise of TGen into daily practice at City of Hope,” Dr. Bryce says. “It’s a connection that benefits the community in Phoenix and far beyond. We’re accelerating the translation of lab findings into new options for patients and linking our strengths in genomics and patient care to develop comprehensive early-detection programs that offer patients better quality of life and better survival rates.”

Growing up in San Diego, California, Dr. Bryce knew he wanted to be an oncologist by the time he was 14. Even at that young age, he understood the need for more doctors dedicated to cancer care and made it his mission to be part of the solution. His biggest career ambition is to cure metastatic prostate cancer. His role on the City of Hope Cancer Center Phoenix leadership team offers him the chance to realize his vision of building an integrated oncology program that’s available to all Arizonans.

Dr. Bryce earned his medical degree from Rosalind Franklin University of Medicine and Science in Chicago, Illinois. At the Mayo Clinic College of Medicine and Science in Rochester, Minnesota, he then completed a residency in internal medicine and a fellowship in hematology/oncology, serving as chief fellow during his tenure. Before joining City of Hope, he was a faculty member at the Mayo Clinic in Arizona for 12 years, ultimately becoming professor and chair of hematology and medical oncology at the Phoenix campus and site director of the Mayo Clinic in Arizona comprehensive cancer center.

As a physician-scientist, Dr. Bryce leads investigations exploring the mutations that appear in cancer cells. His research furthers precision oncology, in which tumor samples undergo genetic testing to individually customize treatment based on the therapies shown to be most effective against the specific molecular characteristics of the disease. He is internationally renowned for his work fostering new prostate cancer drugs from a class called PARP inhibitors, which interfere with tumor cells’ ability to repair themselves.

Dr. Bryce has garnered continuous clinical trials research funding from the National Cancer Institute since 2013. He is also prolific in launching and leading early-phase clinical trials to move innovative treatment protocols into the clinic. As of 2023, Dr. Bryce has co-authored more than 100 peer-reviewed biomedical studies, including in top-tier journals such as the New England Journal of Medicine, the Journal of Clinical Oncology and Lancet Oncology.

Fluent in conversational Japanese, Dr. Bryce enjoys spending his free time with his wife and four sons. His hobbies include swimming, cycling, reading (especially about history), camping, and fishing.